The management of stage III lung cancer is highly individualized based on patient factors and guided by multidisciplinary input, generally including a combination of chemotherapy, radiation therapy, and possible resection if deemed operable.2-3 Tyrosine kinase inhibitors are not yet approved for stage III disease; however, several clinical trials with epidermal growth factor receptor (EGFR) inhibition in the neoadjuvant setting are ongoing (Table 1). This evidence concerns the gene EGFR and lung carcinoma.